One of my most anticipated #ESMO26 presentations: Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC. Roche reports positive PFS and interim OS results. But the effect sizes and full safety data are still pending. https://t.co/9UNJGb7NmH